Association of AXIN2 s2240308 C>T, rs1133683 C>T, rs7224837 A>G Polymorphisms with Susceptibility to Breast Cancer.
AXIN2
Susceptibility
association
breast cancer
polymorphisms
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Aug 2021
01 Aug 2021
Historique:
received:
24
06
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
18
1
2022
Statut:
epublish
Résumé
The association of genetic polymorphisms at Axis inhibition protein 2 (AXIN2) gene and susceptibility to different cancer has attracted much interest. The present study aimed to evaluate the association between AXIN2 rs2240308 C>T, rs1133683 C>T, rs7224837 A>G polymorphisms with susceptibility to breast cancer. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was designed to genotype the AXIN2 rs2240308 C>T, rs1133683 C>T, rs7224837 A>G polymorphisms among 150 breast cancer patients and 150 healthy subjects. The frequencies of these genetic variants were in agreement with Hardy-Weinberg equilibrium in healthy controls (p>0.05). The frequencies of AXIN2 rs2240308 C>T, rs1133683 C>T, rs7224837 A>G genotypes were similar in breast cancer patients and controls. There was no a significant association between the AXIN2 SNP and risk of breast cancer. The impact of AXIN2 polymorphisms in the breast cancer development remains unclear. Our results indicated that AXIN2 rs2240308, rs7224837 and rs1133683 polymorphisms did not contribute to increased risk of breast cancer. More studies with larger sample sizes and diverse ethnicities are warranted to verify our finding.
Sections du résumé
BACKGROUND
BACKGROUND
The association of genetic polymorphisms at Axis inhibition protein 2 (AXIN2) gene and susceptibility to different cancer has attracted much interest. The present study aimed to evaluate the association between AXIN2 rs2240308 C>T, rs1133683 C>T, rs7224837 A>G polymorphisms with susceptibility to breast cancer.
METHODS
METHODS
A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was designed to genotype the AXIN2 rs2240308 C>T, rs1133683 C>T, rs7224837 A>G polymorphisms among 150 breast cancer patients and 150 healthy subjects.
RESULTS
RESULTS
The frequencies of these genetic variants were in agreement with Hardy-Weinberg equilibrium in healthy controls (p>0.05). The frequencies of AXIN2 rs2240308 C>T, rs1133683 C>T, rs7224837 A>G genotypes were similar in breast cancer patients and controls. There was no a significant association between the AXIN2 SNP and risk of breast cancer.
CONCLUSION
CONCLUSIONS
The impact of AXIN2 polymorphisms in the breast cancer development remains unclear. Our results indicated that AXIN2 rs2240308, rs7224837 and rs1133683 polymorphisms did not contribute to increased risk of breast cancer. More studies with larger sample sizes and diverse ethnicities are warranted to verify our finding.
Identifiants
pubmed: 34452579
doi: 10.31557/APJCP.2021.22.8.2717
pmc: PMC8629482
pii:
doi:
Substances chimiques
AXIN2 protein, human
0
Axin Protein
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2717-2722Références
Asian Pac J Cancer Prev. 2015;16(16):7277-84
pubmed: 26514524
NPJ Breast Cancer. 2021 Jun 11;7(1):76
pubmed: 34117267
Neoplasma. 2017;64(2):269-277
pubmed: 28043155
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
J Gastrointest Cancer. 2021 Mar;52(1):80-84
pubmed: 33001376
BMC Cancer. 2021 Apr 1;21(1):353
pubmed: 33794810
Biochem Genet. 2021 Apr;59(2):506-515
pubmed: 33151448
Fetal Pediatr Pathol. 2020 Feb;39(1):29-37
pubmed: 31268379
J Am Dent Assoc. 2009 Jan;140(1):80-4
pubmed: 19119171
Fetal Pediatr Pathol. 2020 Dec;39(6):476-490
pubmed: 31590591
Asian Pac J Cancer Prev. 2015;16(3):1219-24
pubmed: 25735359
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3225-3231
pubmed: 30486620
Mol Pharmacol. 2010 Nov;78(5):827-36
pubmed: 20702762
PLoS One. 2013;8(3):e59555
pubmed: 23516639
Mol Cancer Res. 2020 Sep;18(9):1257-1270
pubmed: 32503922
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2101-8
pubmed: 18708403
Am J Cancer Res. 2020 May 01;10(5):1568-1591
pubmed: 32509398
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2015 May 14;5:10111
pubmed: 25974148
Mol Cancer Res. 2020 Aug;18(8):1113-1128
pubmed: 32430354
J Glob Oncol. 2018 Jul;4:1-16
pubmed: 30085889
J Res Med Sci. 2015 Mar;20(3):284-93
pubmed: 26109977
Chin Neurosurg J. 2020 Aug 3;6:25
pubmed: 32922954
Rep Biochem Mol Biol. 2018 Oct;7(1):30-37
pubmed: 30324115
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-50
pubmed: 26554920
Asian Pac J Cancer Prev. 2012;13(12):6101-4
pubmed: 23464412
J Med Chem. 2021 Apr 22;64(8):4257-4288
pubmed: 33822624
Genes Dis. 2018 May 12;5(2):77-106
pubmed: 30258937
Int J Mol Sci. 2020 Jul 09;21(14):
pubmed: 32659938
Int J Mol Sci. 2020 Oct 18;21(20):
pubmed: 33080952
Genet Test Mol Biomarkers. 2019 Jun;23(6):393-400
pubmed: 31063404
Arch Iran Med. 2021 Mar 01;24(3):209-217
pubmed: 33878879
Mol Cancer. 2020 Nov 24;19(1):165
pubmed: 33234169
Theranostics. 2019 Jan 1;9(2):449-465
pubmed: 30809286
Int J Mol Med. 2006 Aug;18(2):279-84
pubmed: 16820935